Results 101 to 110 of about 17,660,936 (332)

Modern biological/biotechnological medicinal products. Topical issues and prospects for development

open access: yesБиопрепараты: Профилактика, диагностика, лечение, 2018
The review provides with the information, related to the development, research and registration of new biological preparations, including the issues of terminology and classification.
Yu. V. Olefir   +6 more
doaj  

Detecting Elemental Impurities by Inductively Coupled Plasma Mass Spectrometry in Russian Radiopharmaceuticals

open access: yesРегуляторные исследования и экспертиза лекарственных средств
INTRODUCTION. Radiopharmaceutical manufacturers should assess potential negative impact of elemental impurities on the quality of their products using real data of their elemental contamination.
Yu. N. Shvetsova   +6 more
doaj   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

open access: yesMolecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici   +8 more
wiley   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

open access: yesMolecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert   +13 more
wiley   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser   +14 more
wiley   +1 more source

Determination of visible particles in parenteral dosage forms and ophthalmic dosage forms

open access: yesРегуляторные исследования и экспертиза лекарственных средств, 2018
The present article describes the approaches to the choice of methods for assessing the content of visible particles in parenteral and ophthalmic dosage forms, recognized in general pharmacopoeia monograph «Visible particles in parenteral dosage forms ...
Yu. V. Olefir   +7 more
doaj  

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy